Eli Lilly is Picking On Schizophrenics
by Douglas A. McIntyre
Picking on people with schizophrenia would seem to be very unfair. If it is a large corporation, the odds against prople with serious mental illness would really seem to be stacked against them.
Lawyers for patients who suffer from the awful disease have uncovered documents that show that Eli Lilly (LLY) played down the health risks of Zyprexa, the companies best selling drug for treating schizophrenia.The drug can cause weight gain and increase in blood sugar, both of which can cause diabetes.
The drug brings in $4.2 billion a year, so it is not hard to see why Lilly would try to dupe the mentally ill and their doctors.
According to the NY Times internal Lilly documents are "replete with references to Zyprexa’s importance to Lilly’s future and the need to keep concerns about diabetes and obesity from hurting sales"
At least the attorneys for these seriously ill people have a smoking gun.
And, at least Lilly is probably facing a major legal and PR disaster. Not good for the stock.
__________
Related BHI articles:
- Merck Wants Out of Pfizer's Shadow
- GlaxoSmithKline May Benetif from Weak U.S. Dollar
- Searching for Values in the Drug Stock Universe
__________
Picking on people with schizophrenia would seem to be very unfair. If it is a large corporation, the odds against prople with serious mental illness would really seem to be stacked against them.Lawyers for patients who suffer from the awful disease have uncovered documents that show that Eli Lilly (LLY) played down the health risks of Zyprexa, the companies best selling drug for treating schizophrenia.The drug can cause weight gain and increase in blood sugar, both of which can cause diabetes.
The drug brings in $4.2 billion a year, so it is not hard to see why Lilly would try to dupe the mentally ill and their doctors.
According to the NY Times internal Lilly documents are "replete with references to Zyprexa’s importance to Lilly’s future and the need to keep concerns about diabetes and obesity from hurting sales"
At least the attorneys for these seriously ill people have a smoking gun.
And, at least Lilly is probably facing a major legal and PR disaster. Not good for the stock.
__________
Related BHI articles:
- Merck Wants Out of Pfizer's Shadow
- GlaxoSmithKline May Benetif from Weak U.S. Dollar
- Searching for Values in the Drug Stock Universe
__________
posted by Nico at
9:52 AM
1 Comments:
Eli Lilly Zyprexa scandal
Zyprexa off label promotion scandal is all over the news now.
Lilly drug reps are alleged to have called their marketing ploy,"Viva zyprexa".
Eli Lilly zyprexa cost me over $250.00 a month supply out of my own pocket X 4 years and has up to ten times the risk (over non users) of causing diabetes and severe weight gain.
Zyprexa which is only FDA approved for schizophrenia (.5-1% of pop) and some bipolar (2% pop) and then an even smaller percentage of theses two groups.
So how does Zyprexa get to be the 7th largest drug sale in the world?
Eli Lilly is in deep trouble for using their drug reps to 'encourage' doctors to write zyprexa for non-FDA approved 'off label' uses.
The drug causes increased diabetes risk,and medicare picks up all the expensive fallout.There are now 7 states (and counting) going after Lilly for fraud and restitution.
Only 9 percent of adult Americans think the pharmaceutical industry can be trusted right around the same rating as big tobacco.
---
Daniel Haszard zyprexa-victims.com
Post a Comment
Subscribe to Post Comments [Atom]
<< Home